CHRS
- Coherus BioSciences, Inc.
()
Overview
Company Summary
Coherus BioSciences, Inc. (CHRS) is a biopharmaceutical company primarily focused on developing and commercializing high-quality biosimilar drugs. A biosimilar is a biological product, such as a vaccine or medication, that is highly similar to and has no clinically meaningful differences from an existing approved reference product.
Coherus BioSciences specializes in developing biosimilars for various therapeutic areas, including oncology, immunology, and ophthalmology. The company's goal is to improve patient access to lower-cost alternatives to expensive biologic drugs.
Their expertise lies in utilizing advanced analytics, process economics, and state-of-the-art technologies to develop biosimilar products that deliver similar therapeutic benefits as the reference products at a lower cost. By leveraging their scientific capabilities, Coherus aims to expand treatment options and increase affordability for patients and healthcare providers.
Additionally, apart from biosimilar development, the company also focuses on developing novel biologic therapies. These innovative therapies aim to address unmet medical needs in various disease areas and have the potential to improve patient outcomes.
Overall, Coherus BioSciences plays a crucial role in the healthcare industry by providing affordable and effective biologic drugs through biosimilar development and innovative therapies, ultimately benefiting patients, healthcare providers, and the broader healthcare system.